Clinical Trial

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 420 type 2 diabetes patients with early dementia are randomized 1:1 to either the active treatment group (receiving subcutaneous injections of mazdutide weekly, with stepwise dose escalation to a maintenance dose per protocol) or the placebo group (receiving matched placebo injections). The primary objective is to evaluate the potential disease-modifying effects of mazdutide on cognitive dysfunction in type 2 diabetes.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-15; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Recruiting 2025-11-18
Trial Details
NCT Number NCT07083154
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators: Nanjing First Hospital, Nanjing Medical University, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Xiangya Hospital of Central South University, Huadong Hospital, Jiangsu Province Hospital of Traditional Chinese Medicine, Changzhou No.2 People's Hospital, The Second Affiliated Hospital of Dalian Medical University
Conditions Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
Enrollment 420 participants
Start Date 2025-09-27
Primary Completion 2029-08-01 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-05